- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03613688
Effects of Deepure(Pu-erh Tea Extract) on Glycemic Control
October 29, 2018 updated by: Tasly Pharmaceuticals, Inc.
This is a randomized, controlled, cross-over study on the effects of consumption of Deepure puerh tea extract (PTE) on glucose tolerance and metabolic markers.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
The study will involve consuming three different doses: 1 gram, 1.5 grams, and 2 grams, and will be given in warm water, with a bland meal.
The effects on glucose and insulin after consumption will be evaluated.The subjects will be randomly assigned to one of four groups with different sequences.
Study Type
Interventional
Enrollment (Anticipated)
28
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Gitte Jensen
- Phone Number: (541) 884-0112
- Email: gitte@nislabs.com
Study Locations
-
-
Oregon
-
Klamath Falls, Oregon, United States, 97601
- Recruiting
- NIS Labs
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Men and women;
- Aged 18-70 years;
- BMI between 20-30;
- Fasting blood glucose at screening between 71-125 mg/dL. both inclusive.
Exclusion Criteria:
- Taking dietary supplements judged to interfere with the effects of Deepure on glucose metabolism (for example: cinnamon extract; chromium picolinate; mulberry extract; bitter melon extract, green tea extracts, black tea extracts, pu-erh tea);
- Participation in other clinical trials, involving an investigational product or lifestyle change, during the last month;
- Participation in another research study during this trial, involving an investigational product or lifestyle change; Taking prescription medication known to affect glucose metabolism;
- Taking over-the-counter medication known to affect glucose metabolism;
- Drinking 3 or more cups of tea daily;
- Unwilling to abstain from drinking tea for 24 hours before clinic visits; (if a person drinks tea within 24 hours of a clinic visit, the person's visit will be re-scheduled);
- Consuming 2 or more drinks of alcohol per day;
- Unwilling to abstain from drinking alcohol for 10 hours before clinic visits;
- Diagnosed with diabetes Type I; Taking medication for diabetes Type II;
- Diagnosed with the thyroid disorder Hashimoto's disease;
- Past major surgery to your stomach or intestines (minor surgery not a problem such as hernia repair, appendix removal, gallbladder removal);
- Currently taking cholesterol-lowering medication (for example: statins);
- Currently taking coumadin;
- Major trauma within the past 6 months;
- Major surgery within the past 6 months;
- Severe chronic infectious disease (such as HIV, chronic hepatitis);
- Active depression;
- Self-reported eating disorders;
- History of drug abuse during past two years;
- Currently going through intense stressful events or life changes;
- Women of child-bearing potential: Pregnant, breast-feeding, or trying to become pregnant;
- Women of child-bearing potential: Not using effective contraception;
- Food allergies or sensitivities to tea.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Deepure Group A
Visit 3: Warm water without Deepure; Visit 4: Warm water with 1 g Deepure; Visit 5: Warm water with 1.5 g Deepure; Visit 6: Warm water with 2 g Deepure.
|
Pu'erh Tea extract
|
EXPERIMENTAL: Deepure Group B
Visit 3: Warm water with 1 g Deepure; Visit 4: Warm water with 1.5 g Deepure; Visit 5: Warm water with 2 g Deepure; Visit 6: Warm water without Deepure.
|
Pu'erh Tea extract
|
EXPERIMENTAL: Deepure Group C
Visit 3: Warm water with 1.5 g Deepure; Visit 4: Warm water with 2 g Deepure; Visit 5: Warm water without Deepure; Visit 6: Warm water with 1 g Deepure.
|
Pu'erh Tea extract
|
EXPERIMENTAL: Deepure Group D
Visit 3: Warm water with 2 g Deepure; Visit 4: Warm water without Deepure; Visit 5: Warm water with 1 g Deepure; Visit 6: Warm water with 1.5 g Deepure.
|
Pu'erh Tea extract
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Post-prandial glucose response
Time Frame: From baseline to 30, 60, 90, 120, and 180 minutes
|
Change in blood glucose leve after consuming test meal with and without Pu'er tea
|
From baseline to 30, 60, 90, 120, and 180 minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
September 20, 2018
Primary Completion (ANTICIPATED)
June 1, 2019
Study Completion (ANTICIPATED)
July 1, 2019
Study Registration Dates
First Submitted
July 26, 2018
First Submitted That Met QC Criteria
August 1, 2018
First Posted (ACTUAL)
August 3, 2018
Study Record Updates
Last Update Posted (ACTUAL)
October 31, 2018
Last Update Submitted That Met QC Criteria
October 29, 2018
Last Verified
October 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 079-007
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glucose Metabolism Disorders
-
University of AberdeenCompletedMetabolism Disorder, GlucoseUnited Kingdom
-
Columbia UniversityCompletedMetabolism Disorder, GlucoseUnited States
-
University of LeipzigInstitut für Gesundheits- und Praxismanagement GmbHWithdrawn
-
Purdue UniversityAlmond Board of CaliforniaActive, not recruitingGlucose Intolerance | Glucose Metabolism Disorders (Including Diabetes Mellitus)United States
-
University of Missouri-ColumbiaCompletedGlucose | Blood Sugar; High | Glucose Metabolism Disorders (Including Diabetes Mellitus)United States
-
Solvay PharmaceuticalsTerminatedDyslipidemia | Glucose Metabolism DisorderPoland, Croatia, Finland, France, Germany, Netherlands, Romania, Ukraine
-
University of South CarolinaCompletedPhysical Activity | Sedentary Lifestyle | Metabolism Disorder, GlucoseUnited States
-
DLR German Aerospace CenterCompletedGlucose Metabolism Disorders | Local Glucose Uptake
-
Solvay PharmaceuticalsCompletedDyslipidemia/Glucose Metabolism DisorderPoland, Ukraine, United Kingdom
-
Solvay PharmaceuticalsCompletedDyslipidemia/Glucose Metabolism DisorderCzech Republic, France, Hungary, India, Lithuania, Poland, Slovakia